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Mutations that decrease insulin-like growth factor (IGF) and growth hormone signaling limit body size and prolong
lifespan in mice. In vertebrates, these somatotropic hormones are controlled by the neuroendocrine brain. Hormone-
like regulations discovered in nematodes and flies suggest that IGF signals in the nervous system can determine
lifespan, but it is unknown whether this applies to higher organisms. Using conditional mutagenesis in the mouse, we
show that brain IGF receptors (IGF-1R) efficiently regulate somatotropic development. Partial inactivation of IGF-1R in
the embryonic brain selectively inhibited GH and IGF-I pathways after birth. This caused growth retardation, smaller
adult size, and metabolic alterations, and led to delayed mortality and longer mean lifespan. Thus, early changes in
neuroendocrine development can durably modify the life trajectory in mammals. The underlying mechanism appears
to be an adaptive plasticity of somatotropic functions allowing individuals to decelerate growth and preserve
resources, and thereby improve fitness in challenging environments. Our results also suggest that tonic somatotropic
signaling entails the risk of shortened lifespan.
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Introduction
Growth hormone (GH) and insulin-like growth factors
(IGFs) promote mammalian growth [1,2] and contribute to
metabolic regulation [3–5]. In contrast, inhibiting the actions
of GH or IGF extends lifespan: mice constitutively lacking
growth hormone receptor (GHR knockout [6,7]) or GH-
releasing hormone receptor (GHRHR
lit/lit mutant [8,9]), or
mice with fewer IGF receptors [10], no insulin-receptor
substrate 1 (IRS1) [11], or diminished IRS2 [12] live longer.
This powerful effect of insulin-like signals on longevity was
discovered in nematodes [13,14] and insects [15,16], but may
extend to humans: functionally relevant IGF receptor (IGF-
1R) mutations have recently been discovered in centenarians
[17], and conditions of low IGF-I, PI3K, IRS1, GH, and GHRH
correlate with prolonged lifespan [18,19]. Signiﬁcantly, the
regulation of aging in diverse species involves common major
hormonal pathways, and the underlying mechanisms have
clearly been conserved through evolution. Several lines of
evidence suggest that the fundamental biological process
might be an adaptive mechanism enabling individuals to
adjust body size, metabolism, and lifespan to their environ-
ment, in particular to the challenging natural ﬂuctuations of
resources [20–22]. Such an adaptive mechanism would
require individual plasticity, especially of the somatotropic
hormone axis in response to environmental cues. Because the
development of this hormone axis is steered by the central
nervous system (CNS) through hypothalamic control of
pituitary differentiation [23], it is possible that any somato-
tropic plasticity would involve the CNS. Indeed, previous
work in nematodes and insects showed that insulin-like
signals in the nervous system alter survival in a non-cell
autonomous manner [24–29], suggesting that neuronal con-
trol of aging through insulin-like signals might also be
conserved. To test these ideas experimentally in a mammalian
model, we genetically manipulated IGF signaling in the mouse
brain and explored growth, metabolism, and lifespan in these
mutants.
We found that brain IGF receptors strongly promote the
development of the somatotropic function in mice. We show
that developmental IGF signaling in the brain selectively
determines somatotropic plasticity, regulates GH and IGF-I
secretion, and thereby controls growth of peripheral tissues,
adult glucose metabolism, and energy storage, as well as
survival and mortality.
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Brain IGF-1R Regulates Growth Hormone
To study the role of IGF signaling in the CNS, we
generated mice with heterozygous and homozygous brain-
speciﬁc IGF-1 receptor knockout mutations (bIGF1RKO
þ/ 
and bIGF1RKO
 / ) by conditional mutagenesis (Figure 1A
and 1B). Mutants and their controls were littermates with
identical genetic background, and matings were performed
such that the Nestin-Cre transgene was always paternally
transmitted (see Methods and Text S1 for breeding and
genetic background). Homozygous mutants (bIGF1RKO
 / )
have no IGF-1R on CNS neurons or glia. They were
microcephalic and developed a complex phenotype involving
severe growth retardation, infertility, and abnormal behavior
(Figure S1). Though very interesting per se, the homozygous
bIGF1RKO
 /  mice did not show extended lifespan and their
adult plasma IGF-I concentration was signiﬁcantly higher
than control values (Figure S1E and S1G). Thus, homozygous
mutants were not a suitable model for healthy longevity,
which is generally associated with diminished insulin-like
signaling [20,21]. We therefore studied the heterozygous
mutants (bIGF1RKO
þ/ ), in which the IGF-1R levels in the
CNS are half that in the wild-type (Figure 1C). They were
healthy and behaved normally (Figure S2). Their body
growth, however, though initially normal, was progressively
retarded from 20 d of age onwards (Figure 2A). By age 90 d,
bIGF1RKO
þ/  adults weighed about 90% of controls (males,
30.5 6 0.6 g, n ¼ 12 versus 33.7 6 0.4 g,  9.6%, n ¼ 19, p ,
0.0001; females, 24.1 6 0.3 g, n ¼ 18 versus 26.2 6 0.5 g,
 7.9%, n ¼ 14, p , 0.001) and were 5% shorter than controls
(p , 0.001) (Table S1). bIGF1RKO
þ/ mice had normal IGF-1R
levels in peripheral tissues (see Figure 1C), so we speculated
that endocrine growth regulation during development was
disturbed. bIGF1RKO
þ/  pituitaries were indeed small from
age 10 d onwards (Figure 2B), and total GH content remained
low throughout development (Figure 2C). The GH concen-
tration per milligram protein fell at age 20 d, suggesting that
retardation of early postnatal somatotroph differentiation
(Figure 2D) started between day 10 and day 20. Plasma IGF-I,
which strongly depends on GH, did not show any pubertal
increase in bIGF1RKO
þ/  mice while controls displayed the
normal surge (Figure 2E). Moreover, the concentration of the
acid labile subunit (ALS), an important regulator of IGF-I
stability and itself regulated by GH, was very low in mutants
throughout postnatal life (Figure 2F). Importantly, in this
model the IGF-1R gene is knocked out in the hypothalamus
but not in the pituitary (Figure 3A). Therefore, we suspected
that this somatotropic phenotype was caused by alterations
in GH-regulatory neurons of the hypothalamus, i.e. arcuate
nucleus GHRH neurons and anterior periventricular soma-
tostatin (SRIH) neurons whose endings converge on the
Figure 1. Brain-Targeted Inactivation of the Igf1r Gene Using Cre-lox
Mutagenesis
(A) CNS-specific Cre-lox recombination demonstrated using X-Gal
staining (blue) in a sagittal section from a 2-wk-old NesCre
þ/0 mouse
harboring a LacZ reporter (Rosa26R
þ/0) [33]. NesCre is expressed in
neuroepithelium by neuronal and glial precursors. Abbreviations: Br,
brain; FT, fat tissue; He, heart; Int, intestine (with bacterial artifacts); Li,
liver; OE, olfactory epithelium (red arrow).
(B) Southern blot analysis of adult bIGF1RKO
þ/  tissues revealed
complete recombination in the brain (Br) and the intact Igf1r
flox allele
in all peripheral tissues (left panel). Recombination in peripheral tissues
was minimal. The IGF-1R knockout was effective throughout the brain
(right panel) and stable through time (unpublished data). The restriction
enzymes used were HincII and I-SceI (left blot) and HincII alone (right).
Cb, cerebellum, Cx, cortex, Ki, kidney, Lu, lung, M, DNA size marker, M1/
M2, skeletal muscle, Ob, olfactory bulb, Po, pons, Sk, skin, Sp, spleen, St,
striatum, Th, thalamus, Ts, testis.
(C) bIGF1RKO
þ/ mice had normal IGF-1R levels in peripheral tissues (e.g.,
muscle) and ;50% of normal levels in the CNS (here: hypothalamus and
cortex), as assessed by western blotting.
doi:10.1371/journal.pbio.0060254.g001
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Author Summary
Using a mouse model relevant for humans, we showed that lifespan
can be significantly extended by reducing the signaling selectively
of a protein called IGF-I in the central nervous system. This effect
occurred through changes in specific neuroendocrine pathways.
Dissecting the pathophysiological mechanism, we discovered that
IGF receptors in the mammalian brain efficiently steered the
development of the somatotropic axis, which in turn affected the
individual growth trajectory and lifespan. Our work confirms
experimentally that continuously low IGF-I and low growth
hormone levels favor extended lifespan and postpone age-related
mortality. Together with other recent reports, our results further
challenge the view that administration of GH can prevent, or even
counteract human aging. This knowledge is important since growth
hormone is often prescribed to elderly people in an attempt to
compensate the unwanted effects of aging. Growth hormone and
IGF-I are also substances frequently used for doping in sports.external layer of the median eminence (ME). Indeed,
hypothalamic GHRH expression in bIGF1RKO
þ/  mice was
signiﬁcantly low, and GHRH accumulation in the GHRH
neuron endings was clearly diminished around age 10 d
(Figure 3B and 3C). In contrast, hypophysiotropic SRIH-
producing neurons in the hypothalamus exhibited a normal
abundance of SRIH at age 10 d, evidence of the cell-
speciﬁcity of this phenotype (Figure 3B and 3D). Accordingly,
Pit-1 expression, which is controlled by GHRH neurons and
steers somatotropic cell differentiation, was half normal in
mutant pituitaries (Figure 3E).
This early somatotropic deﬁciency persisted: in adult
Figure 2. Growth and Postnatal Development of the Somatotropic Axis
in Mutant and Control Mice
(A) bIGF1RKO
þ/  mice had significantly delayed growth, from age 18 d
onwards.
(B) bIGF1RKO
þ/ pituitaries were small from age 10 d onwards (n¼10 per
group).
(C) Pituitaries from mutants contained little GH (n ¼ 5 per group).
(D) Data from (C) expressed per milligram of pituitary protein revealing a
selective drop at age 20 d.
(E) In control mice, serum IGF-I increased rapidly after age 10 d (in
response to endogenous GH), but remained low in bIGF1RKO
þ/  mice.
(F) Similar to IGF-I (E), the postnatal surge of ALS in controls was absent
from bIGF1RKO
þ/  mice (n ¼ 5 per group).
doi:10.1371/journal.pbio.0060254.g002
Figure 3. Somatotropic Signals in the Hypothalamic-Pituitary Complex
(A) Efficient Cre-lox recombination in hypothalamus, not in pituitary, as
shown by X-Gal-staining of a sagittal NesCre
þ/0;Rosa26R
þ/0 brain section:
the anterior pituitary originates from the pharyngeal wall, not from
neuroepithelium, to which NesCre transgene expression is confined.
Abbreviations: 3V, third ventricle; aP, anterior pituitary; Bo, bone; Hpt,
hypothalamus; Inf, infundibulum; iP, intermediate pituitary; ME, median
eminence; pP, posterior pituitary; R, recessus of the third ventricle. PCR
analysis of genomic DNA confirmed absence of recombination from the
pituitary: intact Igf1r
flox alleles in pituitary, and knockout (Igf1r
 ) alleles
prevalent in hypothalamus.
(B) GHRH immunoreactivity (red) at nerve endings in the ME was weaker
than control in bIGF1RKO
þ/  mice (65 6 6 versus 122 6 10 au (arbitrary
units), p , 0.01, n ¼ 3), whereas SRIH (green) was unaffected (191 6 3
versus 197 6 5 au, n ¼ 3). Briefly, ME tissue sections from the same
anatomical location in three bIGF1RKO
þ/  and three control 10-day-old
males were subjected to IHC. Micrographs were taken under identical
conditions. For each animal, data from ten sections were averaged. The
ratio of GHRH to SRIH immunoreactivity was lower in bIGF1RKO
þ/  than
in control animals (0.34 6 0.05 versus 0.54 6 0.09, n ¼ 6; p ¼ 0.06).
(C) Similarly, GHRH gene expression (measured by quantitative real-time
RT-PCR, relative to b-actin) was lower at age 10 d in mutants than
controls.
(D) SRIH expression was similar in mutants and controls.
(E) Pit-1 expression (relative to 18S rRNA) was lower in bIGF1RKO
þ/ than
wild-type pituitaries at age 10 d.
doi:10.1371/journal.pbio.0060254.g003
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þ/  hypothalamus, the GHRH concentration re-
mained low, while the abundance of antagonistic SRIH
increased (Figure 4A). Consistent with these observations,
adult bIGF1RKO
þ/  pituitaries were small (males,  40%;
females,  33%; p , 0.001; Table S1), contained many fewer
GH-producing cells, and were GH depleted compared with
controls (Figure 4A right, 4B). Peripheral tissues showed
diverse evidence of chronic lack of GH stimulation: Liver GH
receptors were hypersensitive to GH stimulation (Figure 4C),
and several markers of peripheral GH action were abnor-
mally low in adults (IGFBP-3,  37%; ALS,  53%; Figure 4D;
serine protease inhibitor Spi2.1, 53%, unpublished data). As
expected, plasma IGF-I levels were lower in adult
bIGF1RKO
þ/  mice than controls (males, 243 6 10 versus
453 6 15 ng/ml,  46%, p , 0.0001; females, 321 6 13 versus
442 6 16 ng/ml, 27%, p , 0.0001) (Figure 4D, right). Finally,
IGF-1R was consistently underphosphorylated in major
peripheral tissues (e.g. skeletal muscle: between 51% and
67% of control levels, depending on age, as determined by
IGF-1R immunoprecipitation and western immunoblot;
Figure S3), clearly indicating that cells were receiving less
than wild-type IGF-I stimulation.
Gonado- and Thyrotropic Functions Are Preserved
To determine whether the observed hypothalamic inhib-
ition of endocrine GH and IGF-I was speciﬁc, we assessed
gonado- and thyrotropic functions in mutant animals by
monitoring fertility, reproduction, and energy metabolism.
bIGF1RKO
þ/  females were fertile and had normal litters (7.1
6 0.7 pups, n ¼ 6 litters). Ovarian cycling, controlled by
anterior pituitary follicle-stimulating hormone (FSH), lutei-
nizing hormone (LH), and their hypothalamic releasing
hormones, was identical in bIGF1RKO
þ/  and control females
(mean estrous cycle length, at 4 mo of age, 5.1 6 0.3 versus 4.9
6 0.3 d, n¼15, not signiﬁcant [NS]; at ;9 mo of age, 5.3 6 0.2
versus 5.9 6 0.4 d, n ¼ 37, NS). Moreover, there was no
difference in pro-estrus estradiol concentration in adult
females (82.3 6 6.3 versus 85.2 6 5.0 pmol/l, n¼39, NS) nor in
ovary size relative to weight (bIGF1RKO
þ/  0.36 6 0.01 versus
controls 0.38 6 0.02 mg/g, n ¼ 72, NS); therefore we
considered gonadotropic function to be normal. Plasma
thyroxin (T4) levels, controlled by pituitary thyroid-stimulat-
ing hormone (TSH) were unaffected in females (bIGF1RKO
þ/ 
29.1 6 1.4, n ¼ 19 versus controls 27.5 6 1.6 lg/l, n ¼ 12, NS)
and, although they were moderately high in males
(bIGF1RKO
þ/  39.0 6 2.0, n ¼ 14 versus controls 30.0 6 1.0
lg/l, n ¼ 20, p , 0.005), we observed no differences in core
body temperature (males, bIGF1RKO
þ/  36.7 6 0.3 8C versus
controls 37.0 6 0.4 8C, n¼15, NS; females, bIGF1RKO
þ/  37.4
6 0.1 8C versus controls 37.5 6 0.1 8C, n¼21, NS), nor did we
ﬁnd abnormalities in physical activity or food consumption
(Figure S2A and S2B). Hence, we concluded that thyrotropic
function also was in the normal range. In addition, the
development of gonado- and thyrotropic phenotypes be-
Figure 4. GH/IGF-I Deficiency in Adult bIGF1RKO
þ/ 
(A) Hypothalamic GHRH was higher (left) and SRIH lower (middle) in
bIGF1RKO
þ/ thancontrolmiceatage9mo.PituitaryGHwasmarkedlylow
(right). The wet weight of the hypothalamus and total proteins extracted
from hypothalamus in mutants did not differ from control values
(bIGF1RKO
þ/ 1.5560.12mgversuscontrols1.5360.10mg,p¼0.86,NS).
(B) GH immunoreactivity (red) was much lower in bIGF1RKO
þ/  than
control pituitaries, here in frontal sections through the lateral half gland
with DAPI (blue) nuclear counter-stain. aP, anterior pituitary; iP,
intermediate pituitary; pP, posterior pituitary.
(C) Liver GH receptor (upper) and Jak2 (lower panel) were over-
phosphorylated upon administration of GH into the portal vein,
indicating hypersensitivity of GHR (n ¼4 per group; paired t-test). Right:
representative western blots.
(D) IGF-binding protein-3 (IGFBP-3, left), ALS (middle), and circulating
IGF-I (right) were significantly less abundant in bIGF1RKO
þ/  mice than
controls, indicative of deficient peripheral GH action. IGFBP-3 and ALS
(and also Spi2.1, see text) were determined only in males.
doi:10.1371/journal.pbio.0060254.g004
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differed thereafter.
Energy Storage Is Altered in bIGF1RKO
þ/  Mice
Weight gain with age was slightly greater for adult
bIGF1RKO
þ/  mice than for controls (unpublished data),
such that female mutants ﬁnally attained the same weight as
controls. We analyzed body composition in 10-mo-old
animals, and as suggested by growth curves and circulating
IGF-I levels, most organs in bIGF1RKO
þ/  mice were smaller
than those in controls (Table S1). Adipose tissue (AT), in
contrast, was signiﬁcantly enlarged in males and females
(Figure 5A; Table S2). In both sexes, the largest increase was
in subcutaneous AT, whereas visceral AT was less increased in
mutant females, and even slightly diminished in males, similar
to other GH-deﬁcient mouse models [30–32]. Accordingly,
circulating leptin levels were excessive in bIGF1RKO
þ/  mice
(males, 27.1 6 3.6 ng/ml versus 7.4 6 1.2 ng/ml; females, 15.5
6 1.0 ng/ml versus 6.5 6 0.5 ng/ml; both p , 0.0001; Figure
5B). At age 4 mo, blood biochemistry in bIGF1RKO
þ/  mice
was still normal (Table S3), but at 10 mo, HDL and total
cholesterol concentrations were high (unpublished data) and
triglyceride (TG) and free fatty acid (FFA) concentrations in
males signiﬁcantly higher than in controls, probably due to
the abundance of AT (TG, 1.36 6 0.12 mmol/l versus 1.03 6
0.09 mmol/l, n ¼ 10 per group, p , 0.05; FFA, 0.65 6 0.04
mmol/l versus 0.48 6 0.03 mmol/l, n ¼ 10 per group, p ,
0.005). As circulating GH counteracts fat storage, these
metabolic traits may be secondary to the observed somato-
tropic defect.
Mice with peripheral resistance to IGF-I or with low GH
and IGF-I activity generally display altered glucose metabo-
lism [3,10,33,34]. We therefore assessed glucose tolerance and
insulin secretion in adult bIGF1RKO
þ/  mice and found
moderate, but signiﬁcant hyperglycemic responses in males
and females (Figure 5C). Moreover, although insulin secretory
response 30 min after glucose injection appeared adequate in
bIGF1RKO
þ/  females, it was relatively insufﬁcient in
bIGF1RKO
þ/  males (Figure 5D). The impaired control of
glucose homeostasis and enlarged fat tissue in adult mutants
indicate that the lack of IGF-I and GH progressively affected
bIGF1RKO
þ/  metabolism.
bIGF1RKO
þ/  Mice Live Longer Than Controls
Constitutive inactivation of GHRH or GH receptors, as well
as mutations impeding pituitary somatotroph development,
increase longevity [6,9,35]. We therefore measured the
lifespan of bIGF1RKO
þ/  and control mice. Survival curves
showed that bIGF1RKO
þ/  mice had a signiﬁcantly longer
mean lifespan than control littermates (914 6 21 d, n ¼ 27
versus 836 6 28 d, n ¼ 42, p , 0.05) (Figure 6A). When we
analyzed male and female mutants separately, we found
similar increases in longevity (Figure 6B and 6C). However,
the maximum life span was unchanged. The mortality rate for
bIGF1RKO
þ/  mice up to 100 wk of age was six times lower
than for controls (bIGF1RKO
þ/  0.037 versus controls 0.238, p
, 0.05). Thereafter, however, mortality rate of bIGF1RKO
þ/ 
increased sharply and was 55% higher for 121- to 140-wk-old
bIGF1RKO
þ/  mice than controls in the same age range.
Consequently, the inter-individual variation of lifespan was
signiﬁcantly lower for bIGF1RKO
þ/  mice than for controls
(Figure S4). Thus, survival and mortality patterns in
bIGF1RKO
þ/  mice under normal conditions were clearly
affected. In contrast, we did not ﬁnd differences in survival
when mutants where challenged with acute oxidative stress
(Figure S5), indicating that causes other than stress resistance
were important for increased lifespan of bIGF1RKO
þ/  mice.
Post-mortem histopathology revealed a similarly diverse,
heterogeneous panel of diseases in bIGF1RKO
þ/  and control
mice. To allow statistical evaluation despite relatively few
observations, we categorized pathologies as inﬂammatory,
degenerative, or tumor-related. The prevalence of inﬂamma-
tory diseases was similar (bIGF1RKO
þ/  28% versus control
mice 30%), but bIGF1RKO
þ/  mice tended to develop fewer
degenerative diseases (22% versus 27%, NS) and fewer
tumors (44% versus 53%, NS). Notably, none of the
bIGF1RKO
þ/  animals over 130 wk of age showed pituitary
tumors or hyperplasia, whereas 20% of the controls did, most
Figure 5. Exploration of Adult Energy Metabolism
(A) bIGF1RKO
þ/  adipocytes from inguinal AT were abnormally enlarged.
(B) Leptinemia was very high in bIGF1RKO
þ/  mice, and strongly
correlated with individual total AT size in all animals (R ¼ 0.76, p ,
0.0001, n ¼ 82).
(C) Glucose tolerance was impaired in bIGF1RKO
þ/  males and females.
(D) 30 min after intraperitoneal glucose injection (T30), the plasma insulin
concentration was, as expected, significantly increased in mutants and
controls. However, although bIGF1RKO
þ/  females responded to
elevated blood glucose with adequate hyperinsulinemia, bIGF1RKO
þ/ 
males did not, suggesting a secretory defect.
doi:10.1371/journal.pbio.0060254.g005
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However, as control animals had a fully normal lifespan,
pituitary pathology was apparently not precipitating death. It
was more likely that the reduced somatotropic tone in
mutant mice protected them from death at an age by which a
signiﬁcant proportion of controls had already died. Con-
cerning the prevalence of pathologies among those controls
that die earlier than bIGF1RKO
þ/ , our data were non-
conclusive, essentially due to the limited number of observa-
tions. Similarly, we could not ﬁnd published information on
early pathogenesis in B6/129 F1 hybrids. Finally, fewer
bIGF1RKO
þ/  individuals than controls presented multiple
pathologies at death (17% versus 47%, p ¼ 0.2), consistent
with a lower disease burden in mutants.
Discussion
IGF and Somatotropic Plasticity
We showed that diminishing IGF-1R expression in the
brain selectively reduced somatotropic function. This result
suggests that brain IGF-1R controls the set-up of the GH/IGF
axis, thereby modulating growth, energy metabolism, and
lifespan. In contrast, complete absence of brain IGF-1R in the
homozygous knockout produced a very different phenotype
leading to increased IGF-I; thus, the phenotype is strongly
dependent on IGF-1R gene dose. Any life-prolonging effects
of early growth retardation in the homozygous mutant were
subsequently suppressed, possibly by increased IGF-I. How-
ever, phenotypic alterations in the homozygote were so
complex that comparing them with the heterozygote seemed
a futile endeavor. Interestingly, brain-speciﬁc inactivation of
IRS2, a major signal transduction molecule downstream from
IGF-1R and insulin receptors, increased lifespan and altered
nutrient homeostasis [12], while apparently not involving the
somatotropic axis.
The heterozygous bIGF1RKO
þ/  phenotype was somato-
troph-speciﬁc and other neuroendocrine pathways were
unaffected, implicating hypothalamic GHRH neurons. IGF
receptors are indeed present in the arcuate nucleus where
GHRH neurons reside. There is, however, little evidence for a
speciﬁc developmental role for IGF-I in the regulation of
GHRH neurons, and we cannot exclude the possibility that
IGF-1R deletion from other brain areas affected GHRH
neurons at a distance. Nevertheless, the similitude of
bIGF1RKO
þ/  mice with mutants lacking GHRH neurons
[36] or GHRH receptors [9] also indicated that this phenotype
could have been caused by reduced GHRH signals to the
pituitary. Importantly, the number of GH-producing cells in
bIGF1RKO
þ/  pituitaries was only a fraction of that in
controls. This ﬁnding was corroborated by immunohisto-
chemistry (IHC) and concordant with the several-fold
reduced pituitary GH content. GH depletion, in turn,
explains the very low ALS concentration and absence of the
pubertal surge in IGF-I. As the reduction in GHRH was
proportionate to hypothalamic IGF-1R dose, GHRH action
presumably triggers a disproportionate loss of GH cells.
Several mechanisms may contribute to this: GHRH regulates
the number of GH-positive cells, as well as GH production
and secretion. Most likely, GHRH abundance must be above a
certain threshold to stimulate hypothalamic-pituitary devel-
opment and GH production. Moreover, not only GHRH but
also SRIH neurons, which determine adult GH secretion, may
be sensitive to IGF. SRIH was indeed above control
concentrations in the adult bIGF1RKO
þ/  hypothalamus,
suggesting that coordinate GHRH and SRIH action on
somatotrophs may have contributed to the observed over-
proportionate effects.
GHRH and SRIH accumulate in nerve endings at the ME,
and are liberated into portal veins to regulate pituitary GH.
During development, somatotroph proliferation and differ-
entiation depend on local GHRH. In bIGF1RKO
þ/  hypothal-
amus, immunoreactive GHRH but not SRIH was less
abundant than in controls. This difference in amount
suggests a shift from GHRH to SRIH stimulation at the ME
and has possible functional implications for pituitary devel-
opment, e.g. via Pit-1. Early lack of GHRH in ME, as observed
here, may be due to less GHRH neurons, fewer nerve endings,
or diminished GHRH. Although we cannot conclude from
our experiments, IGF receptors in the ME of adult
bIGF1RKO
þ/  appeared to be less phosphorylated than those
in the rest of the hypothalamus (38.8 6 2.6 versus 59.0 6 4.9,
arbitrary units, p¼0.005, n¼8; no difference in control mice;
Figure 6. Lifespan Analysis
(A) Survival curves show that bIGF1RKO
þ/  mice, on average, outlived their control littermates, although the maximum lifespan was similar for mutants
and controls.
(B and C) Separate survival curves for males and females. Mean lifespan for bIGF1RKO
þ/  males was 966 6 28 d versus 853 6 43 d for male controls;
Mean lifespan for bIGF1RKO
þ/  females was 888 6 27 d versus 821 6 36 d for female controls. Differences were significant in Cox’s test for males,
females, and for both sexes combined when curves were censored before week 140, 130, and 135, respectively.
doi:10.1371/journal.pbio.0060254.g006
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Brain IGF Receptors Control Growth and LifespanFigure S3B). Thus, ME may participate in somatotropic
control, for instance by sensing circulating IGF-I. The ME also
harbors numerous tanycytes, glia specialized in IGF-I trans-
port to the brain, that may contribute to the modulation of
somatotropic signals by acting on the maturation of GHRH
neurons. Our various ﬁndings combine to indicate that IGF-I,
the principal peripheral mediator of GH action, itself plays a
major role in the development of the GH/IGF axis.
Cells in small organisms communicate trophic status via
paracrine insulin-like signals [37]. Our results suggest that
IGF-I may have conserved a role of this type in complex
organisms and act, in particular, during development as a
trophic signal that represents numerous, distant tissues [38].
The neuroendocrine network of GHRH, SRIH, and GH cells
evolved in vertebrates as a central regulator that coordinates
growth of heterogeneous cell populations. Here, we describe
a mechanism that determines the individual postnatal
trajectory of the somatotropic axis and its adult set point.
Somatotropic plasticity, as we observed here, may have
evolved to adjust growth to environmental resources. We
further demonstrated that early dietary restriction can
trigger a neuroendocrine response similar to brain-speciﬁc
IGF-1R knockout (see Text S1, Supplementary Results and
Figure S6). Both genetic and nutritional intervention led to
growth deﬁcits and a lifelong reduction in endocrine IGF-I.
Thus, it appears that a fairly direct hormonal path connects
nutrition, somatotropic hormones and growth through a
positive feedback (Figure S7). This view is supported by
recent evidence that AT, a major indicator of postnatal
nutrition, is an important source of IGF-I [39]. Also, the
phylogenetically related insulin receptor (IR) on pancreatic
b-cells controls development of the insulin/IR hormone axis
in a very similar manner [3,4].
Heterozygous inactivation of brain IGF-1R led to a
consistent somatotropic deﬁcit, but without any detectable
effects on other brain functions. Interestingly, we found that
in the bIGF1RKO
þ/  brain, the remaining IGF receptors were
overphosphorylated in the cerebral cortex (120% 6 5% of
controls, n ¼ 16, p , 0.05; Figure S3A) but not in
hypothalamus. This cortical IGF-1R activation may be due
to a compensatory local increase of ligand. In contrast,
complete absence of IGF-1R in bIGF1RKO
 / mutants (Figure
S1) resulted in microcephaly, indicative of a neurotrophic
role for IGF-1R. We conclude that the IGF-1R gene is
heterosufﬁcient with respect to neurotrophic action, but
heteroinsufﬁcient with regard to its role in regulating
somatotropic plasticity.
We showed that downregulation of somatotropic hormones
postponed mortality and increased mean lifespan. The
underlying developmental mechanism suggested that neuro-
endocrine control of lifespan may be physiologically relevant
in mammals. Indeed, somatotropic plasticity may confer an
evolutionary advantage: adaptation of individual body size to
available resources would improve ﬁtness in the face of
environmental changes; control of size, energy metabolism,
and lifespan contribute to preserving vital resources and to
maintaining genetic diversity during periods of shortage.
Therefore, the evolutionary signiﬁcance of somatotropic
plasticity may be that it cushions otherwise deleterious effects
of selective pressure.
The Barker hypothesis and predictive adaptive response
(PAR) hypothesis claim that changes in development can have
late consequences for health, modify mortality and lifespan,
and entail a risk of maladaptation later in life, if environ-
mental conditions differ grossly from those that led to the
initial changes [40,41]. This may apply to bIGF1RKO
þ/  mice,
adapted to a poor environment (little IGF signaling to the
brain), when food was available ad libitum. The resulting
dyslipidemia and hyperglycemia in bIGF1RKO
þ/  mutants
may explain the rapid increase in late-life mortality and
unusual combination of extended mean but normal max-
imum lifespan. Similar patterns of survival have been
described in other aging models: in Caenorhabditis elegans,
ablation of ASI sensory neurons that modulate DAF-2
pathways in response to environment, increased mean, but
not maximum lifespan [27]; in Drosophila, targeted expression
of human uncoupling protein 2 in adult neurons [42], or
inhibition of p53 speciﬁcally in the nervous system [43],
extended mean, but not maximum, lifespan. Common to
these models is that the mutations were targeted to the
nervous system, and it is possible that the perturbed neuronal
responsiveness to environmental cues is the primary cause of
prolonged lifespan in these models.
An alternative interpretation of our ﬁndings with
bIGF1RKO
þ/  mice is possible. The average lifespan of the
mutants was longer than controls, but its variability was half
than that for controls. Thus, individuals on the short-lived
edge of the normal lifespan distribution (see Figures 6 and S4)
beneﬁt most from reduced growth hormone and IGF-I: they
respond with a lifespan extension of nearly 40%. This ﬁnding
raises the question of why genetically homogeneous wild-type
populations display large variability in lifespan. A current
explanation is that initially small stochastic differences
between individuals are subsequently ampliﬁed during
development and adult life; however, the mechanism for this
remains unclear. Our data indicate that a full complement of
brain IGF-1R is required for generating a high somatotropic
tone, and this eventually increases the risk of dying early. This
mechanism may produce much of the lifespan heterogeneity
observed in wild-type mice. Remarkably, the variability of
plasma GH was several-fold higher in controls than in
bIGF1RKO
þ/  mice, the mutants having continuously low
GH levels (M. Holzenberger, L. Kappeler, and A. Bekaert,
unpublished data). There are indeed other mammalian
species where short lifespan can be related to elevated
somatotropic signaling, and vice-versa. In dogs, small size and
low IGF-I are determined by one particular IGF-I allele [44],
and small breeds live twice as long as large breeds [45]. Van
Heemst et al. [19] investigated the relationship between
somatotropic function, adult height, and longevity in
humans, and found that in women, genetically determined
low GH and IGF-I signaling was beneﬁcial for old age survival.
Recently, functionally relevant IGF-1R mutations were
isolated from human centenarians [17]. Persisting high GH
in acromegalic patients after surgical treatment is predictive
of premature death [46], and elevated IGF-I in elderly
individuals correlates with increased mortality [47]. Further-
more, the average lifespan of people with pituitary gigantism
(mean height 236 cm, n ¼ 28) is only 44 y, roughly 20 y below
the corresponding historical adult life expectancy. It would
be extremely valuable to measure the consequences of
somatotropic tone for human health and longevity in a
variety of contexts to clarify these important issues.
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Mouse genetics. Igf1r
ﬂox mice [48,49] were maintained in a 129/Sv
(129) genetic background and also backcrossed to C57BL/6 (B6) for
.15 generations. The Nestin-Cre (NesCre) transgene (maintained in
B6 for .15 generations) produces Cre recombinase in neural and
glial precursors during early neural development [50]. By mating
Igf1r
ﬂox/þ females (B6) with NesCre
þ/0 males we generated Igf1r
ﬂox/
þ;NesCre
þ/0 double mutants in a B6 background. These were mated
with Igf1r
ﬂox/ﬂox females (129) to produce experimental cohorts as fully
reproducible F1 generations of B6/129 hybrid genetic background,
composed of hetero- (þ/ ) and homozygous ( / ) brain-speciﬁc IGF-
1R knockout mice (bIGF1RKO) and their littermate controls. F1
hybrids from pure inbred strains combine two advantages: reprodu-
cibility of genetic composition and so-called hybrid vigor, i.e. the
absence of phenotypic defects that affect pure inbred strains. F1
hybrids are generally long-lived, like mice from mixed genetic
backgrounds and some pure inbred strains, including C57BL/6. We
conducted experiments according to institutional guidelines for the
care of laboratory animals.
Mice. Animals lived under SPF conditions in individually venti-
lated cages at 23 8C, with a 14/10-h light/dark cycle and free access to
water and a commercial rodent diet (49% carbohydrate, 24%
protein, 5% lipid, 12% humidity, 10% mineral, and ﬁber). Mice
were separated from mothers on day 30 and housed six males or six
females per cage, with both control and mutant genotypes in each
cage. Cages were equipped with a mouse house to enhance social
interaction and prevent male aggressiveness. We produced four
cohorts. In cohort 1 (105 bIGF1RKO
þ/ , 116 control males) we
analyzed somatotropic development. To minimize litter effects, they
were trimmed to four to six pups per mother. For experiments,
mutants and controls were always litter-matched and each group was
composed of animals from at least three different litters. In cohort 2
(57 bIGF1RKO
þ/ , 51 controls) we studied growth, metabolism,
behavior, hormones, and body composition. In cohort 3 (45
bIGF1RKO
þ/ , 60 controls) we analyzed additional blood variables,
female fertility, and ovarian function. Mice of cohort 4 (27
bIGF1RKO
þ/ , 19 bIGF1RKO
 / , 42 controls) were checked daily,
but otherwise left undisturbed until they died naturally. Single
surviving females were housed with neighbors. Necropsy was
performed on all animals. Brain, heart, lung, liver, kidney, and spleen
were dissected post mortem and ﬁxed in formalin for histology. We
determined major pathologies present at death for 62 of the 88
animals.
Postnatal growth. Mice were weighed daily until the age of 6 wk
and weekly thereafter. For growth curves, we used sliding means of
current weight and weight on the preceding and subsequent day (or
week, for age .6 wk).
Fertility and reproduction. Estrous cycle length was determined by
daily monitoring of vaginal smear histology for 3 to 4 wk. Blood and
ovaries were sampled between 11 a.m. and 14 p.m. on the pro-estrus
day under pentobarbital anesthesia. Mean litter size was calculated
from matings between bIGF1RKO
þ/  females and wild-type males.
Body temperature. Rectal temperature was determined on three
consecutive days. Measurement began within 10 s of immobilization,
to avoid artifacts of stress-induced thermogenesis.
Histology and immunohistochemistry. LacZ staining was per-
formed on parasagittal 14-lm-thick cryosections from 2-wk-old
double transgenic NesCre
þ/0;Rosa26R
þ/0 mice [33]. Rosa26R
þ/0 litter-
mates served as negative controls. Sections were ﬁxed in PAF, stained
with X-Gal overnight and counterstained with orange G. Inguinal fat
pads from males were quickly frozen and cryosections (50 lm; 30 8C)
ﬁxed in 4% paraformaldehyde (PAF) for hematoxylin staining. Digital
micrographs in visible light were taken with an Olympus BX51
microscope. We detected GH in the pituitary, and GHRH and SRIH
in the ME using standard ﬂuorescent IHC. Sections 18 lm thick were
ﬁxed in PAF and incubated overnight with rabbit anti-GH (NIH-
NIDDK), rabbit anti-GHRH, or goat anti-SRIH antibodies (Santa
Cruz). Secondary antibodies were Alexa 546 goat anti-rabbit and
Alexa 488 donkey anti-goat (Molecular Probes). For ﬂuorescent IHC
we used an Olympus BX612 microscope. To compare the relative
intensities of IHC signals for GH, GHRH, and SRIH between mutants
and controls, we processed all samples under identical conditions
with respect to anatomical location, antibody incubation, laser
intensity, and CCD image acquisition, in particular using identical
parameters of signal integration. For each animal, data obtained from
ten different tissue sections were averaged. Means were then
compared between groups using Student’s t-test.
Western blotting. Immunoprecipitation and western blotting were
as described previously [51]. Antibodies used were anti-IGF-1R b-
subunit (C20, Santa Cruz), anti-phospho-tyrosine (PY20, Trans-
duction Laboratories), anti-mouse GHR (from G. Gudmundur and
F. Talamantes), anti-ALS (AF1436, R&D Systems), anti-mouse P-Jak2
Tyr1007/1008 (Cell Signalling/Ozyme), anti-b-tubulin (Oncogene
Research), and anti-b-actin (Sigma). We conﬁrmed equal loading for
each immunoblot. Bound antibody was revealed using peroxidase-
conjugated secondary antibodies and ECL (Amersham Pharmacia
Biotech). Signals were quantiﬁed using MacBas 2.5 (Fuji) or ﬁlm
autoradiography and NIH Image (for ALS).
Biochemistry. From blood samples we determined total bilirubin,
HDL, and total cholesterol, triglycerides, creatinine, glucose, lactate,
total protein, urea and total antioxidant status, using an Olympus
Diagnostic Automat. We tested glucose tolerance in animals fasted
for 14 h by intraperitoneal injection of 20%-D-glucose (2 g/kg body
weight): glucose was assayed in tail blood at 0, 15, 30, 60, and 120 min
using a hand-held photometer (Lifescan Glucotouch); insulinemia
was measured at 0 and 30 min. We used RIA to determine plasma
IGF-I (Diagnostic Systems Laboratories), insulin, leptin (both from
Linco), and T4 (MP Biomedical). Estradiol concentrations were
determined by RIA in 150 ll of mouse pro-estrus serum (Diasorin).
Pituitary GH content was measured using a rat-speciﬁc RIA (Linco).
GHRH and SRIH were quantiﬁed in sonicated hypothalami by RIA
[52]. The BCAssay (Uptima UP40840A, Interchim) was used to
determine pituitary and hypothalamic protein content.
GH receptor stimulation. Human recombinant GH (Serono) was
injected into the portal vein of mice (0.5 lg/g body weight) under
isoﬂurane anesthesia (Abbott Laboratories). Liver biopsies, taken at
the time of injection and 2, 5, and 20 min later were immediately
frozen for protein extraction.
Real-Time Reverse Transcription-PCR. Total RNA from hypothal-
ami and pituitaries were extracted with phenol-chloroform (RNAble;
Eurobio) and aliquots of 1 lg were reverse transcribed (Transcriptor;
Roche) using random hexamers (Promega) in the presence of RNAsine
(Promega). Duplicates of 10 ng cDNA were used for real-time PCR
ampliﬁcation in an Applied Biosystem’s PCR System 7300 and its
reagents (GHRH, Mm00439100_m1; SRIH, Mm00436671_m1; NPY,
Mm00445771_m1; Pit-1, Mm00476852_m1; GH, Mm00433590_g1;
PRL, Mm005599949_m1; TSH-b, Mm00437190_m1; LH-b,
Mm00656868_q1; b-actin, 4352933E; 18S rRNA, 4333760F). We
quantiﬁed mRNA using standard curves generated with a control
sample and values were normalized to values for housekeeping gene
mRNAs.
Statistics. For group comparison, we used two-tailed Student’s t-
test. Means are expressed 6 SEM. We determined the signiﬁcance of
survival curves by Cox’s test, and used paired t, Mann-Whitney, and
Chi
2 tests where indicated. Levels of signiﬁcance were *, p , 0.05; **,
p , 0.01; ***, p , 0.001; NS, not signiﬁcant (p   0.05).
Supporting Information
Figure S1. Phenotype of Mice with Homozygous IGF-1R Knockout in
the CNS (bIGF1RKO
 / )
Homozygous knockout brains contained 11% of control IGF-1R
levels (29 6 2 fmol/mg versus 278 6 22 fmol/mg, n ¼ 14, determined
by in vitro ligand-binding assay; unpublished data) stemming from
cells of non-neuroepithelial origin, including blood vessels and
meninges.
(A) Unlike heterozygous bIGF1RKO
þ/ , the homozygotes were growth
retarded at birth (;80% of normal birth weight), and their cranium
was ﬂat.
(B) bIGF1RKO
 /  mice were viable, but grew slowly (here at 6 wk of
age).
(C) Frontal brain sections from adult bIGF1RKO
 /  mutants revealed
marked microcephaly.
(D) After severe growth retardation, bIGF1RKO
 /  mice caught up
with normal size at around 4 mo (left panel) and body weight at 12 mo
was not different from control littermates (right panel; data represent
males).
(E) bIGF1RKO
 /  mice showed the same average lifespan as controls
(835 d 6 34 d, n ¼ 19 control 836 d 6 28 d, n ¼ 42). Male and female
data were very similar and thus combined.
(F) Adult bIGF1RKO
 /  mice had elevated fasting glycemia and were
markedly glucose intolerant.
(G) Serum IGF-I was signiﬁcantly decreased at 4 wk, but increased at 8
wk. IGF-I levels continued to be 30%–40% increased throughout
adult life (unpublished data). bIGF1RKO
 /  did not perform in
standard behavioral testing.
Found at doi:10.1371/journal.pbio.0060254.sg001 (308 KB PDF).
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Brain IGF Receptors Control Growth and LifespanFigure S2. Activity, Nutrition, and Behavioral Analysis
(A) Circadian proﬁles of physical activity were identical in
bIGF1RKO
þ/  and control mice. Males and females behaved similarly
and are shown together.
(B) Daily food (left) and water consumption (right) did not differ
between bIGF1RKO
þ/  mice and controls.
(C) Short term spatial memory was unaffected in bIGF1RKO
þ/  males
(right) and females (left): in all groups, mice preferred to explore the
new area in a Y-maze.
(D) bIGF1RKO
þ/  mice behaved similarly as controls in the open ﬁeld
test (unpublished data). However, exploratory behavior was selec-
tively impaired in bIGF1RKO
þ/  males as shown by the novel object
test.
(E) When testing anxiety in an O-maze, bIGF1RKO
þ/  females and
controls behaved similarly, whereas bIGF1RKO
þ/  males were less
anxious (p , 0.05, Mann-Whitney test). Note that males of B6/129-F1
hybrid genetic background generally display higher levels of anxiety
than females [2]. Collectively, we did not ﬁnd signiﬁcant behavioral
differences, other than slightly impaired exploration and reduced
anxiety in bIGF1RKO
þ/  males.
Found at doi:10.1371/journal.pbio.0060254.sg002 (92 KB PDF).
Figure S3. Activation of IGF-1R in Adult bIGF1RKO
þ/  Brain
(A) IGF-1R was signiﬁcantly underphoshorylated in mutant muscle
(hind-limb) and hypothalamus, and overphosphorylated in cerebral
cortex.
(B) When ME was separated from the rest of the hypothalamus,
underphophorylation located to ME only. * p , 0.05, ** p , 0.01, ***
p , 0.001; (au), arbitrary units.
Found at doi:10.1371/journal.pbio.0060254.sg003 (52 KB PDF).
Figure S4. Variation of Lifespan and Mortality in bIGF1RKO
þ/ (Blue)
and Control Mice (Red)
(A) Proportion of mice that died within a given age range. The
distribution was signiﬁcantly narrower in bIGF1RKO
þ/  mice
compared to controls (p , 0.01; F-test). 80% of the mutant mice
died within a 33-wk interval, whereas the same proportion of control
deaths occurred over a 69-wk period.
(B) Mortality in control mice showed a normal increase with age.
Mortality in bIGF1RKO
þ/  mutants occurred much later but
increased rapidly after 120 wk. Mortality above 150 wk was 1.0 for
both groups.
Found at doi:10.1371/journal.pbio.0060254.sg004 (52 KB PDF).
Figure S5. Short-Term Survival of 3-Mo-old bIGF1RKOþ/  Mice
Challenged with Oxidative Stress bIGF1RKO
þ/  and Control Males
Received 60 mg/kg diquat (A) (n ¼ 13 and 10) or 500 mg/kg
Acetaminophen (B) (n ¼ 13 and 14) as a Single Intraperitoneal
Injection
No statistically signiﬁcant differences existed between groups.
Methods are as described in [10]; if more than one animal died
within the same hour they were represented together in one data
point.
Found at doi:10.1371/journal.pbio.0060254.sg005 (43 KB PDF).
Figure S6. Early Postnatal Nutrient Restriction in Wild Type Mice
Inhibited the Development of Somatotropic Function
(A) Nutrient restriction was achieved by increasing the litter size at
birth to ten sucklings per mother, resulting in less mother’s milk, and
comparing with litters trimmed to six sucklings, which ensured
normal nutrient supply. After 2 wk, all mice were fed with rodent
chow ad libitum. Growth of restricted mice was progressively delayed
(p , 0.001, from day 2 onwards).
(B) Left: early nutrient restriction reversibly diminished leptinemia.
Glycemia and other nutritional markers behaved similarly (unpub-
lished data). Right: hypothalamic GHRH expression (relative to b-
actin) was signiﬁcantly decreased in restricted mice at 10 d.
(C) Pituitary GH content was conspicuously low in restricted mice at
20 d, while plasma IGF-I was decreased under nutrient restriction and
also thereafter, under ad libitum feeding.
Found at doi:10.1371/journal.pbio.0060254.sg006 (76 KB PDF).
Figure S7. Functional Development of the Somatotropic Axis
Depends on IGF-1R Signaling
Collectively, our results suggest that the functional development of
the somatotropic axis depends on IGF-1R signaling (left drawing).
Reduced IGF-I signaling in the brain during early life, as with
bIGF1RKO
þ/  mice, retards somatotropic development and leads to
adult GH deﬁciency. Reversely, it is possible that IGF-I, produced as a
normal response to nutrition, stimulates brain IGF-1R and induces
GHRH and Pit-1 production, eventually translating as a positive
feedback into increased GH and IGF-I [3]. This would be different
from adult physiology (right drawing), characterized by negative
feedback of peripheral IGF-I to hypothalamic IGF-1R, thereby
inhibiting GHRH and GH secretion [34,4,5]. It seems possible that
this neuroendocrine plasticity of somatotropic function during early
postnatal development determines individual endocrine life trajec-
tories.
Found at doi:10.1371/journal.pbio.0060254.sg007 (45 KB PDF).
Table S1. Adult Body Composition at 10 mo of Age
Found at doi:10.1371/journal.pbio.0060254.st001 (56 KB DOC).
Table S2. AT in Percent of Body Weight
Found at doi:10.1371/journal.pbio.0060254.st002 (52 KB DOC).
Table S3. Blood Biochemistry at 4 mo of Age
Found at doi:10.1371/journal.pbio.0060254.st003 (47 KB DOC).
Text S1. Supplementary Results
Found at doi:10.1371/journal.pbio.0060254.sd001 (74 KB DOC).
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